Clinical Trial Update: A Phase I Dose Escalation Study of SGN-35 Alone and in Combination With Gemcitabine for CD30-Positive Malignancies [Phase 1]

View source ↗

Summary

An early-phase Phase I dose-escalation study of Brentuximab vedotin (SGN-35) alone and in combination with gemcitabine for CD30-positive malignancies has been t…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Anaplastic Large Cell Lymphoma
• Hodgkin Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Adcetris (Brentuximab vedotin)
• Gemzar (gemcitabine)

Snippet

Sponsor: Seagen Inc. | Conditions: Disease, Hodgkin, Lymphoma, Large-Cell, Anaplastic | Phase 1 | Status: TERMINATED